tailieunhanh - báo cáo hóa học:" Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation"

Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học quốc tế đề tài : Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation | Journal of Translational Medicine BioMed Central Open Access Activation of human B cells by the agonist CD40 antibody CP-870 893 and augmentation with simultaneous toll-like receptor 9 stimulation Erica L Carpenter1 Rosemarie Mick2 4 Jens Ruter1 2 3 and Robert H Vonderheide 1 2 3 Address 1Abramson Family Cancer Research Institute University of Pennsylvania School of Medicine Philadelphia PA 19104 USA 2Abramson Cancer Center University of Pennsylvania School of Medicine Philadelphia PA 19104 USA 3Division of Hematology-Oncology Department of Medicine University of Pennsylvania School of Medicine Philadelphia PA 19104 USA and 4Department of Biostatistics and Epidemiology University of Pennsylvania School of Medicine Philadelphia PA 19104 USA Email Erica L Carpenter - erical@ Rosemarie Mick - rmick@ Jens Ruter - Robert H Vonderheide - rhv@ Corresponding author Published II November 2009 Received 10 August 2009 _ I IO ÍIz-rn roi 1 a- Accepted 1 1 November 2009 Journal of Translational Medicine 2009 7 93 doi 1479-5876-7-93 This article is available from http content 7 1 93 2009 Carpenter et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background CD40 activation of antigen presenting cells APC such as dendritic cells DC and B cells plays an important role in immunological licensing of T cell immunity. Agonist CD40 antibodies have been previously shown in murine models to activate APC and enhance tumor immunity in humans CD40-activated DC and B cells induce tumor-specific T cells in vitro. Although clinical translation of these findings for patients with cancer has been previously limited